Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Breast Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 139 results found since Jan 2013.
Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPAR γ and CaMKII signaling pathway
Breast cancer is the most prevalent malignancy among women. Doxorubicin (Dox) resistance was one of the major obstacles to improving the clinical outcome of breast cancer patients. The purpose of this study was to investigate the relationship between the FABP signaling pathway and Dox resistance in breast cancer. The resistance property of MCF-7/ADR cells was evaluated employing CCK-8, Western blot (WB), and confocal microscopy techniques. The glycolipid metabolic properties of MCF-7 and MCF-7/ADR cells were identified using transmission electron microscopy, PAS, and Oil Red O staining. FABP5 and CaMKII expression levels w...
Source: Frontiers in Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Source Type: research
VPS34-IN1 induces apoptosis of ER + breast cancer cells via activating PERK/ATF4/CHOP pathway
Biochem Pharmacol. 2023 Jun 6:115634. doi: 10.1016/j.bcp.2023.115634. Online ahead of print.ABSTRACTVPS34-IN1 is a specific selective inhibitor of Class III Phosphatidylinositol 3-kinase (PI3K) and has been shown to exhibit a significant antitumor effect in leukemia and liver cancer. In current study, we focused on the anticancer effect and potential mechanism of VPS34-IN1 in estrogen receptor positive (ER + ) breast cancer. Our results revealed that VPS34-IN1 inhibited the viability of ER + breast cancer cells in vitro and in vivo. Flow cytometry and western blot analyses showed that VPS34-IN1 treatment induced breast can...
Source: Biochemical Pharmacology - June 8, 2023 Category: Drugs & Pharmacology Authors: Qiuya Wu Duanfang Zhou Zhengze Shen Bo Chen Gang Wang Lihong Wu Limei Zhang Xiaoli Li Lie Yuan Yuanli Wu Na Qu Weiying Zhou Source Type: research
Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
Discussion: To our best knowledge, our study pioneered co-delivery system for hydrophilic siCD47 and hydrophobic R848. It can maximize break tumor immune escape caused by CD47 and simultaneously enhance antigen presentation by activating DCs for effector T cell killing while regulating the tumor microenvironment as expected. Not only does it conform to the reports of previous basic research, but also it can break the bottleneck of their clinical application hopefully. Collectively, our findings could lay the foundation for future therapeutic strategies of TNBC.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research
Cathepsin G-Induced Cell Aggregation of Breast Cancer MCF-7 Decreases Doxorubicin Sensitivity in a Hypoxia-Inducible Factor-Independent Mechanism
Biol Pharm Bull. 2022;45(12):1772-1783. doi: 10.1248/bpb.b22-00447.ABSTRACTSolid tumors habitually harbor regions with insufficient oxygen away from vasculature. Hypoxia is an important factor that confers malignant phenotypes like chemoresistance to tumor cells. We have demonstrated that cathepsin G (CG) stimulates cell aggregation in breast cancer MCF-7 cells by activating insulin-like growth factor-1 signaling. We investigated whether cancer cell aggregates induced by CG acquire hypoxia-dependent chemoresistance. Pimonidazole staining and hypoxia-inducible factor (HIF)-1α and -2α expression indicated that the core of ...
Source: Biological and Pharmaceutical Bulletin - November 30, 2022 Category: Drugs & Pharmacology Authors: Riyo Morimoto-Kamata Shun Matsuki Naoki Ohkura Satoru Yui Source Type: research
Advancement of cell-penetrating peptides in combating triple-negative breast cancer
Drug Discov Today. 2022 Sep 10:103353. doi: 10.1016/j.drudis.2022.103353. Online ahead of print.ABSTRACTExtensive research efforts have been made and are still ongoing in the search for an ideal anti-cancer therapy. Almost all chemotherapeutics require a carrier or vehicle, a drug delivery system that can transport the drug specifically to the targeted cancer cells, sparing normal cells. Cell-penetrating peptides (CPPs) provide an effective and efficient pathway for the intra-cellular transportation of various bioactive molecules in several biomedical therapies. They are now well-recognized as facilitators of intracellular...
Source: Drug Discovery Today - September 13, 2022 Category: Drugs & Pharmacology Authors: Mahak Fatima Mohammed A S Abourehab Geeta Aggarwal Gaurav K Jain Amirhossein Sahebkar Prashant Kesharwani Source Type: research
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
This study aimed at investigating the influence of commercial transfection reagents (Prime-Fect, Leu-Fect A, and Leu-Fect C) complexed with different siRNAs (CDC20, HSP90, Mcl-1 and Survivin) in MDA-MB-436 breast cancer cells and the impact of incorporating an anionic additive, Trans-Booster, into siRNA formulations for improving in vitro gene silencing and delivery efficiency. Gene silencing was quantitatively analyzed by real-time RT-PCR while cell proliferation and siRNA uptake were evaluated by the MTT assay and flow cytometry, respectively. Amongst the investigated siRNAs and transfection reagents, Mcl-1/Prime-Fect co...
Source: Investigational New Drugs - July 14, 2022 Category: Drugs & Pharmacology Source Type: research
Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
ConclusionThese findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.
Source: Pharmaceutical Research - June 17, 2022 Category: Drugs & Pharmacology Source Type: research
Combinational Silencing of Components Involved in JAK/STAT Signaling Pathway
In conclusion, the promising results of simultaneous targeting of JAK2 and gp 130 might be an example for potential combinatorial silencing strategies in cancer treatment.PMID:35680032 | DOI:10.1016/j.ejps.2022.106233
Source: European Journal of Pharmaceutical Sciences - June 9, 2022 Category: Drugs & Pharmacology Authors: Emira Bousoik Parvin Mahdipoor Abdulelah Alhazza Hamidreza Montazeri Aliabadi Source Type: research
